Communiqués Vivani Medical, Inc.

Actions

VANI

US92854B1098

Temps réel estimé Cboe BZX Autres places de cotation 16:41:16 01/07/2024			Varia. 5j.	Varia. 1 janv.
1,265 ^USD	-0,39 %		+1,60 %	+24,51 %

13/06	Vivani Medical déclare que la FDA américaine a approuvé la demande de nouveau médicament de recherche pour un traitement potentiel du diabète de type 2	MT
13/06	Vivani Medical, Inc. annonce que la FDA autorise la demande de nouveau médicament de recherche et lève la suspension clinique pour le NPM-119, un implant miniature de médicament GLP-1 subdermique à long terme	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant	13/06	BU
Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant	28/05	BU
Vivani Medical : 2024 Investor Presentation	14/05	PU
Vivani Medical: Q1 Earnings Snapshot	13/05	AQ
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results	13/05	BU
Vivani Medical to Present at TIDES Conference 2024	09/05	BU
Vivani Medical : 2024 Investor Presentation	26/03	PU
Vivani Medical: Q4 Earnings Snapshot	26/03	AQ
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	26/03	BU
Vivani Medical Appoints Daniel Bradbury to its Board of Directors	06/03	BU
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants	04/03	AQ
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants	01/03	BU
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic, Wegovy	29/02	AQ
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio	28/02	BU
Vivani Medical: Q3 Earnings Snapshot	14/11	AQ
Vivani Medical Provides Business Update and Reports Third Quarter Financial Results	14/11	BU
Vivani Medical to Present at BIO Investor Forum	16/10/23	BU
Vivani Medical : 2023 Investor Presentation	18/09/23	PU
Vivani Medical to Present at the Boulder Peptide Symposium	07/09/23	BU
Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10	05/09/23	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Vivani Medical, Inc.

Actions

VANI

US92854B1098

Communiqués

Filtres